Lowest-Rated Stocks NYSE:NVTA Invitae - NVTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.69 +0.28 (+11.62%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.52▼$2.9350-Day Range$1.71▼$2.9752-Week Range$1.67▼$12.04Volume19.50 million shsAverage Volume8.94 million shsMarket Capitalization$653.40 millionP/E RatioN/ADividend YieldN/APrice Target$6.90 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Invitae MarketRank™ ForecastAnalyst RatingHold1.67 Rating ScoreUpside/Downside156.5% Upside$6.90 Price TargetShort InterestHealthy17.01% of Shares Sold ShortDividend StrengthN/ASustainability-1.16Upright™ Environmental ScoreNews Sentiment0.23Based on 8 Articles This WeekInsider TradingSelling Shares$114,644 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.42) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector282nd out of 1,030 stocksMedical Laboratories Industry8th out of 25 stocks 2.8 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on no buy ratings, 8 hold ratings, and 4 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.90, Invitae has a forecasted upside of 156.5% from its current price of $2.69.Amount of Analyst CoverageInvitae has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted17.01% of the outstanding shares of Invitae have been sold short.Short Interest Ratio / Days to CoverInvitae has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Invitae has recently decreased by 5.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 70.65% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.16. Previous Next 2.9 News and Social Media Coverage News SentimentInvitae has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Invitae this week, compared to 4 articles on an average week.Search Interest23 people have searched for NVTA on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.MarketBeat Follows10 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $114,644.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Invitae is held by insiders.Percentage Held by Institutions76.79% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($2.42) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Invitae (NYSE:NVTA) StockInvitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.Read More Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comInvitae (NYSE:NVTA) Shares Gap Down to $2.48February 1, 2023 | americanbankingnews.comInvitae (NYSE:NVTA) Stock Price Up 3.5%February 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! February 1, 2023 | americanbankingnews.comAnalysts Set Invitae Co. (NYSE:NVTA) Target Price at $8.45January 31, 2023 | americanbankingnews.comThe Goldman Sachs Group Lowers Invitae (NYSE:NVTA) to SellJanuary 30, 2023 | finance.yahoo.comInvitae Appoints William H. Osborne to its Board of DirectorsJanuary 9, 2023 | finance.yahoo.comInvitae Reports Preliminary 2022 Financial ResultsJanuary 8, 2023 | finance.yahoo.comInvitae to Present at the 41st Annual J.P. Morgan Healthcare ConferenceFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 21, 2022 | finance.yahoo.comThe one-year earnings decline has likely contributed toInvitae's (NYSE:NVTA) shareholders losses of 89% over that periodDecember 20, 2022 | finance.yahoo.comInvitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc.December 7, 2022 | finance.yahoo.comInvitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic ResearchDecember 1, 2022 | finance.yahoo.comInvitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental DiseasesNovember 29, 2022 | finance.yahoo.comIs Invitae in Danger of Running Out of Money?November 15, 2022 | finance.yahoo.comWhy Shares of Invitae Rose 11% on TuesdayNovember 10, 2022 | finance.yahoo.comInvitae Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2022 | finance.yahoo.comWhy Invitae Stock Is Crushing It TodayNovember 9, 2022 | finance.yahoo.comInvitae (NVTA) Q3 2022 Earnings Call TranscriptOctober 31, 2022 | finance.yahoo.comInvitae study shows therapy informed by genetic testing reduces seizures in some patients with epilepsyOctober 28, 2022 | finance.yahoo.comIs Invitae Stock a Buy Now?October 25, 2022 | finance.yahoo.comInvitae to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022October 19, 2022 | finance.yahoo.comWith 83% ownership of the shares, Invitae Corporation (NYSE:NVTA) is heavily dominated by institutional ownersOctober 11, 2022 | streetinsider.comWHAT TO LOOK FOR WHEN NAVIGATING PERSONAL RISKS FOR BREAST CANCER - StreetInsider.comOctober 7, 2022 | globenewswire.comUS Genetic Testing Market Size to Hit USD 10.29 Billion by 2027 - GlobeNewswireOctober 3, 2022 | thestreet.comWould Exact Sciences Acquire Invitae? Unlikely. - TheStreetOctober 2, 2022 | fool.com.auInvitae (NYSE: NVTA) Share Price and NewsSeptember 27, 2022 | finance.yahoo.comInvitae Appointed to National Quality Forum Committee on Quality Standards for HealthcareSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address NVTA Company Calendar Last Earnings11/08/2022Today2/02/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees3,000Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.90 High Stock Price Forecast$18.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+156.5%Consensus RatingHold Rating Score (0-4)1.67 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($13.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-379,010,000.00 Net Margins-617.65% Pretax Margin-626.73% Return on Equity-39.04% Return on Assets-17.75% Debt Debt-to-Equity Ratio10.03 Current Ratio6.44 Quick Ratio6.18 Sales & Book Value Annual Sales$460.45 million Price / Sales1.42 Cash FlowN/A Price / Cash FlowN/A Book Value$13.16 per share Price / Book0.20Miscellaneous Outstanding Shares242,900,000Free Float240,224,000Market Cap$653.40 million OptionableOptionable Beta1.86 Key ExecutivesKenneth D. KnightChief Executive Officer & DirectorRoxi WenChief Financial OfficerRobert L. NussbaumChief Medical OfficerKarthik SuriChief Product & Technology OfficerEric OlivaresChief Science OfficerKey CompetitorsCastle BiosciencesNASDAQ:CSTLProgenityNASDAQ:PROGCareDxNASDAQ:CDNADermTechNASDAQ:DMTKCelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 5,493 shares on 2/2/2023Ownership: 0.013%Redwood Wealth Management Group LLCBought 40,850 shares on 2/1/2023Ownership: 0.017%Zurcher Kantonalbank Zurich Cantonalbank Bought 8,862 shares on 2/1/2023Ownership: 0.017%Bank of Montreal CanSold 290,200 shares on 2/1/2023Ownership: 0.000%Sumitomo Mitsui Trust Holdings Inc.Sold 19,190 shares on 1/30/2023Ownership: 7.104%View All Insider TransactionsView All Institutional Transactions NVTA Stock - Frequently Asked Questions Should I buy or sell Invitae stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 4 sell ratings and 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares. View NVTA analyst ratings or view top-rated stocks. What is Invitae's stock price forecast for 2023? 12 equities research analysts have issued twelve-month target prices for Invitae's shares. Their NVTA share price forecasts range from $2.00 to $18.00. On average, they anticipate the company's share price to reach $6.90 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts. How have NVTA shares performed in 2023? Invitae's stock was trading at $1.86 on January 1st, 2023. Since then, NVTA shares have increased by 46.8% and is now trading at $2.73. View the best growth stocks for 2023 here. When is Invitae's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our NVTA earnings forecast. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) announced its quarterly earnings results on Tuesday, November, 8th. The medical research company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.17. The medical research company earned $133.54 million during the quarter, compared to the consensus estimate of $132.80 million. Invitae had a negative trailing twelve-month return on equity of 39.04% and a negative net margin of 617.65%. What guidance has Invitae issued on next quarter's earnings? Invitae issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $122.00 million-$122.00 million, compared to the consensus revenue estimate of $121.46 million. What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA). When did Invitae IPO? (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. What is Invitae's stock symbol? Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA." Who are Invitae's major shareholders? Invitae's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.15%), Sumitomo Mitsui Trust Holdings Inc. (7.10%), Bourne Lent Asset Management Inc. (0.08%), Green Alpha Advisors LLC (0.06%), Redwood Wealth Management Group LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.02%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen. View institutional ownership trends. How do I buy shares of Invitae? Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Invitae's stock price today? One share of NVTA stock can currently be purchased for approximately $2.73. How much money does Invitae make? Invitae (NYSE:NVTA) has a market capitalization of $663.12 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.84) on an earnings per share basis. How many employees does Invitae have? The company employs 3,000 workers across the globe. How can I contact Invitae? Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com. This page (NYSE:NVTA) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.